2024 annual financial data
Sutro Biopharma 2024 Operating cash flow margin
Direct answer
Operating cash flow margin was -308.72%.
Operating income was -238.45M USD and net income was -227.46M USD.
Operating cash flow was -191.54M USD.
Get free Sutro Biopharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 62.04M USD
- Operating income
- -238.45M USD
- Net income
- -227.46M USD
- Operating cash flow
- -191.54M USD